Innate Sensing of Cell-Free DNA and the Interferon-Mediated Control of HIV In Vivo

无细胞 DNA 的先天感知和体内干扰素介导的 HIV 控制

• 批准号: 10661305
• 负责人: Satish Kumar Pillai
• 金额: $ 27.7万
• 依托单位: VITALANT
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-23 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10661305
• 关键词: Advanced Development; Aftercare; Aging; Apoptosis; Biological Markers; Blood Circulation; CD4 Positive T Lymphocytes; Cell Death; Cells; Characteristics; Chronic; Clinical; Clinical Oncology; Collection; Cytidine Deaminase; Data; Death Rate; Disease; Disease remission; Evaluation; Exhibits; HIV; HIV Antibodies; HIV Infections; Human body; Immune; Immunologics; Individual; Inflammation; Inflammatory; Integration Host Factors; Interferon Type I; Interferons; Interruption; Kinetics; Link; Measurement; Measures; Mediating; Mitochondria; Mitochondrial DNA; Molecular; Morbidity - disease rate; Nucleic Acids; Pharmacology; Phenotype; Plasma; Plasma Cells; Predisposition; Recrudescences; Recurrence; Refractory; Sampling; Selection for Treatments; Signal Transduction; Study Section; System; Time; Viral; Virus Latency; antiretroviral therapy; antiviral immunity; cancer diagnosis; cell free DNA; cytokine; diagnostic strategy; disorder risk; experience; extracellular vesicles; in vivo; interest; liquid biopsy; macrophage; methylome; mitochondrial dysfunction; monocyte; mortality; next generation sequencing; prevent; prognostic significance; response; uptake; viral rebound

PROJECT SUMMARY While the advent of antiretroviral therapy (ART) has dramatically reduced the morbidity and mortality associated with HIV infection, a cure is not achieved due to the persistence of latently-infected cells during treatment. Accumulating data suggest that HIV-infected individuals often experience persistent immune dysregulation, chronic inflammation, and accelerated aging even in the setting of ART-mediated viral suppression. These realities have created a pronounced interest in developing strategies to cure HIV infection. Identifying the host molecular determinants of HIV persistence and rebound kinetics following cessation of antiretroviral therapy (ART) will be critical in developing effective strategies to cure HIV infection. We recently applied a comprehensive systems profiling approach to plasma samples from HIV-infected individuals who underwent analytical treatment interruption (ATI), to identify circulating host factors that enable prediction of HIV rebound kinetics following ART interruption, and serve as potential pharmacological targets to promote durable virologic remission in the absence of ART. The host factor exhibiting the strongest statistical association with HIV rebound timing following ART cessation was circulating cell-free DNA (cfDNA) in plasma. Specifically, increased cfDNA abundance in plasma was associated with delayed time-to-rebound. cfDNA, released into circulation during programmed cell death, has been exploited extensively in the realm of clinical oncology (often termed “liquid biopsy”). However, cfDNA remains largely unexplored in the setting of HIV infection. In this R01 proposal, we rigorously explore cfDNA as a biomarker of HIV disease states, and we investigate the molecular and immunologic mechanisms linking cfDNA to viral expression and rebound. Our central hypotheses are that 1) cfDNA reflects the death rate of HIV-infected cells in vivo; and 2) cfDNA promotes an antiviral state in the host (e.g. induction of type I interferon response) which prevents viral rebound. Our project features an investigative team with basic, translational, and clinical expertise, and leverages large collections of clinical samples from well-characterized HIV-infected individuals. In Aim 1, we will apply next-generation sequencing (NGS) approaches to plasma samples from HIV-infected individuals to validate and enhance the prognostic significance of cfDNA as a biomarker of natural HIV control in vivo. In Aim 2, we will evaluate how the uptake and sensing of cfDNA by HIV target cells impacts cell fate and the reactivation and replication of HIV. In Aim 3, we will determine how HIV-associated mitochondrial dysfunction leads to cfDNA extrusion and ultimately induces type I interferon responses that prevent HIV rebound. Our project will advance the development and evaluation of HIV cure strategies.

项目总结 而抗逆转录病毒疗法(Art)的出现大大降低了发病率和死亡率。 与艾滋病毒感染相关的是，由于潜伏感染细胞在 治疗。越来越多的数据表明，艾滋病毒感染者通常会经历持久的免疫 即使在ART介导的病毒环境中，调节失调、慢性炎症和加速衰老也是如此 压制。这些现实使人们对制定治疗艾滋病毒感染的战略产生了明显的兴趣。 确定HIV持续存在和停止感染后反弹动力学的宿主分子决定因素 抗逆转录病毒疗法(ART)将是制定治愈艾滋病毒感染的有效策略的关键。我们最近 对艾滋病毒感染者的血浆样本应用了全面的系统分析方法 接受分析治疗中断(ATI)，以确定循环宿主因素，使预测 HIV在ART中断后的反弹动力学，并作为潜在的药理靶点来促进 在没有抗逆转录病毒治疗的情况下，持久的病毒学缓解。显示出最强统计特性的主机因素 与抗逆转录病毒治疗停药后HIV反弹时间相关的是循环中的无细胞DNA(CfDNA) 血浆。具体地说，血浆中cfDNA丰度的增加与反弹时间延迟有关。 CfDNA在细胞程序性死亡过程中被释放到循环中，已被广泛利用于 临床肿瘤学(通常称为“液体活检”)。然而，cfDNA在很大程度上仍未在 艾滋病毒感染。在这份R01提案中，我们严格探索cfDNA作为艾滋病毒疾病状态的生物标记物，我们 研究cfDNA与病毒表达和反弹的分子和免疫学机制。 我们的中心假设是：1)cfDNA反映体内感染艾滋病毒的细胞的死亡率；以及2) CfDNA促进宿主体内的抗病毒状态(例如诱导I型干扰素反应)， 防止病毒反弹。我们的项目以一个调查团队为特色，包括基础、翻译和临床 专业知识，并利用来自特征良好的艾滋病毒感染者的大量临床样本。 在目标1中，我们将对艾滋病毒感染者的血浆样本应用下一代测序(NGS)方法 验证和加强cfDNA作为自然HIV控制生物标志物的预后意义的个人 在活体内。在目标2中，我们将评估HIV靶细胞对cfdna的摄取和感知如何影响细胞命运。 以及艾滋病毒的重新激活和复制。在目标3中，我们将确定艾滋病毒相关线粒体是如何 功能障碍导致cfDNA排出，最终诱导I型干扰素反应，从而预防HIV 抢篮板球。我们的项目将推进艾滋病毒治疗策略的开发和评估。